StockNews.AI
IBRX
StockNews.AI
25 days

ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates

1. ImmunityBio reported $26.4M revenue in Q2 2025, up 60% from Q1. 2. ANKTIVA® unit sales grew 246% in 1H 2025 compared to 2H 2024.

Earnings
-4.98%Current Return
VS
+0.42%S&P 500
$3.0107/25 06:14 AM EDTEvent Start
$2.8607/28 06:26 AM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Very Bullish?

ImmunityBio's strong revenue growth and substantial unit sales increase signal robust market performance. Historical examples show similar revenue spikes previously correlated with stock price surges.

How important is it?

The reported revenue growth and sales increase are critical for IBRX's financial health, making them highly relevant to its immediate stock performance. Such metrics are often focal points for investor decision-making.

Why Short Term?

The immediate financial results and growth metrics typically affect stock price in the near term, especially in quarterly reports. Past instances demonstrate that substantial quarterly growth influences investor sentiment quickly.

Related Companies

NASDAQ: ANKNASDAQ: BMYNASDAQ: PFE
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced preliminary financial results for the fiscal quarter ended June 30, 2025, and clinical progress across its pipeline. Key Highlights Q2 2025 Revenue Growth with Continued Strong Sales Momentum: $26.4 million, up 60% from Q1 2025, with year-to-date sales of ~$43 million. ANKTIVA® Unit Growth Since J-Code: 246% unit sales volume growth in 1H 2025 compared to 2H 2024. Cash Positi.

Related News